Acquired slow-channel syndrome: A form of myasthenia gravis with prolonged open time of the acetylcholine receptor channel

Annals of Neurology

Volumn 44, Issue 4, 1998, Pages 657-664

  Wintzen, Axel R ^a,d   Plomp, Jaap J ^a   Molenaar, Peter C ^a   Van Dijk, J Gert ^a   Van Kempen, Gertrudis T H ^a   Vos, Renske M ^b   Wokke, John H J ^b   Vincent, Angela ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR;

ADULT; ARTICLE; CASE REPORT; ENDPLATE POTENTIAL; FEMALE; HUMAN; MUSCLE CONTRACTION; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; PRIORITY JOURNAL; SYNDROME; SYNDROME DELINEATION; THYMECTOMY; THYMUS HYPERPLASIA;

ADULT; ANIMALS; AUTOANTIBODIES; BLOOD; CALCIUM CHANNELS; ELECTROMYOGRAPHY; ELECTROPHYSIOLOGY; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INTERCOSTAL MUSCLES; ION CHANNEL GATING; ION CHANNELS; MICE; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; TIME FACTORS;

EID: 0031783967     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440412     Document Type: Article

References (48)

1. Vincent A. Immunology of acetylcholine receptors in relation to myasthenia gravis. Physiol Rev 1980;60:756-824
2. Drachman DB. Myasthenia gravis: immunobiology of a receptor disorder. Trends Neurosci 1983;11:446-451
3. Kao I, Drachman DB. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science 1977;196:527-529
4. Lennon VA. Immunofluorescence analysis of surface acetylcholine receptors on muscle: modulation by autoantibodies. In: Jenden DJ, ed. Cholinergic mechanisms and psychopharmacology. New York: Plenum Press, 1978:77-92
5. Sahashi K, Engel AG, Lambert EH, Howard FM Jr. Ultrastructural localization of the terminal and lytic ninth complement (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 1980;39:160-172
6. Gomez CM, Richman DP. Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia. Proc Natl Acad Sci USA 1983;80:4089-4093
7. Fels G, Plumer-Wilk R, Schreiber M, et al. A monoclonal antibody interfering with binding and response ot the acetylcholine receptor. J Biol Chem 1986;261:15746-15754
8. Dolly JO, Gwilt M, Lacay G, et al. Action of antibodies directed against the acetylcholine receptor on channel function at mouse and rat motor endplates. J Physiol (Lond) 1988;399: 577-589
9. Maselli RA, Nelson DJ, Richman DP. Effects of a monoclonal anti-acetylcholine receptor antibody on the avian end-plate. J Physiol (Lond) 1989;411:271-283
10. Burges J, Wray D, Pizzighellia S, et al. A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro. Muscle Nerve 1990;13:407-413
11. Bufler J, Kahlert S, Tzartos S, et al. Activation and blockade of mouse muscle nicotinic channels by antibodies directed against the binding site of the acetylcholine receptor. J Physiol (Lond) 1996;492:107-114
12. Elmqvist D, Hofman WW, Kugelberg T, Quastel DMJ. An electrophysiological investigation of neuromuscular transmission in myasthenia gravis. J Physiol (Lond) 1964;174:417-434
13. Fambrough DM, Drachman DB, Satyamurti S. Neuromuscular junction in myasthenia gtavis: decreased acetylcholine receptors. Science 1973;182:293-295
14. Engel AG, Lindstrom JM, Lambert EH, Lennon VA. Ultra-structural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model. Neurology 1977;27:307-315
15. Ito Y, Miledi R, Vincent A, Newsom-Davis J. Acetylcholine receptors and end-plate electrophysiology in myasthenia gravis. Brain 1978;101:345-368
16. Toyka KV, Drachman DB, Pestronk A, Kao I. Myasthenia gravis: passive transfer from man to mouse. Science 1975;190: 397-399
17. Toyka KV, Drachman DB, Griffin DE, et al. Myasthenia gravis: study of humoral immune mechanisms by passive transfer to mice. N Engl J Med 1977;296:125-131
18. Molenaar PC, Polak RL, Miledi R, et al. Acetylcholine in intercostal muscle from myasthenia gtavis patients and in tat diaphragm after blockade of acetylcholine receptors. Prog Brain Res 1979;49:449-458
19. Cull-Candy SG, Miledi R, Trautmann A, Uchitel OD. On the release of transmitter at normal, myasthenic gravis and myasthenic syndrome affected human end-plates. J Physiol (Lond) 1980;299:621-638
20. Plomp JJ, Van Kempen GThH, De Baets M, et al. Acetylcholine release in myasthenia gravis: regulation at single end-plate level. Ann Neurol 1995;37:627-636
21. Newsom-Davis J, Willcox N, Schluep M, et al. Immunological heterogeneity and cellular mechanisms in myasthenia gravis. Ann NY Acad Sei 1987;505:12-26
22. Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. Lancet 1986;1:116-119
23. Drachman DB, de Silva S, Ramsay D, Pestronk A. Humoral pathogenesis of myasthenia gtavis. Ann NY Acad Scei 1987;505: 90-105
24. Burges J, Vincent A, Molenaar PC, et al. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 1994;17: 1393-1400
25. Yamamoto T, Vincent A, Ciulla TA, et al. Seronegative myasthenia gravis: a plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM. Ann Neurol 1991;30:550-557
26. Mossman S, Vincent A, Newsom-Davis J. Passive transfer of myasthenia gravis by immunoglobulins: lack of correlation between AChR with antibody bound, acetylcholine teceptor loss and transmission defect. J Neurol Sci 1988;84:15-28
27. Van Dijk JG, Tjon-A-Tsien AML, Van der Kamp W. CMAP variability as a function of electrode size and site. Muscle Nerve 1995;18:68-73
28. Oh SJ. Electromyography. Neuromuscular transmission studies. Baltimore: Williams and Wilkins, 1988
29. Van Dijk JG, Lammers GJ, Wintzen AR, et al. Repetitive CMAPs: mechanisms of neural and synaptic genesis. Muscle Nerve 1996;19:1127-1133
30. Beeson D, Jacobson L, Newsom-Davis J, et al. A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis. Neurology 1996;47:1552-1555
31. Motomura M, Johnston I, Lang B, et al. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995;58:85-87
32. Jennekens FGI, Hesselmans LFGM, Veldman H, et al. Deficiency of acetylcholine receptors in a case of end-plate acetylcholinesterase deficiency: a histochemical investigation. Muscle Nerve 1992;15:63-72
33. Hong SJ, Chang CC. Transmitter-mediated local contracture of the endplate region of the focally innervated mouse diaphragm treated with anticholinesterase. Br J Pharmacol 1993;109: 1178-1185
34. Dau PC. Plasmapheresis: therapeutic of experimental procedure? Arch Neurol 1984;41:647-652
35. Blom RJ, Kuks JBM, Westerterp-Maas A, et al. Favorable results of plasmapheresis in severe myasthenia gravis. Ned Tijdschr Geneeskd 1997;141:381-384
36. Bhattacharyya BJ, Day JW, Gundeck JO, et al. Desensitization of mutant acetylcholine receptors in transgenic mice reduces the amplitude of neuromuscular synaptic currents. Synapse 1997; 27:367-377
37. Jennekens FGI, Veldman H, Wokke JHJ. Histology and pathology of the human neuromuscular junction with a description of the clinical features of the myasthenic syndromes. In: De Baets MH, Oosterhuis HJGH, eds. Myasthenia gravis. Boca Raton, FL: CRC Press, 1993:99-145
38. Engel AG, Lambert EH, Mulder DM, et al. A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann Neurol 1982;11:553-569
39. Oosterhuis HJGH, Newsom-Davis J, Wokke JHJ, et al. The slow channel syndrome: two new cases. Brain 1987;110:1061-1079
40. Sine SM, Ohno K, Bouzat C, et al. Mutation of the acetylcholine receptor subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity. Neuron 1995;15: 229-239
41. Ohno K, Hutchinson DO, Milone M, et al. Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the epsilon subunit. Proc Nad Acad Sci USA 1995;92:758-762
42. Gomez CM, Gammack JT. A leucine-to-phenylalanine substitution in the acetylcholine receptor ion channel in a family with the slow-channel syndrome. Neurology 1995;45:982-985
43. Gomez CM, Maselli R, Gammack J, et al. A β-subunit mutation in the acetylcholine receptor channel gate causes severe slow-channel syndrome. Ann Neurol 1996;39:712-723
44. Milone M, Wang HL, Ohno K, et al. Slow-channel myasthenic syndrome caused by enhanced activation, desensitization, and agonist binding affinity attributable to mutation in the M2 domain of the acetylcholine receptor alpha subunit. J Neurosci 1997;17:5651-5665
45. Croxen R, Newland C, Beeson D, et al. Mutations in different functional domains of the human muscle acetylcholine receptor alpha subunit in patients with the slow channel congenital myasthenic syndrome. Hum Mol Genet 1997;6:767-774
46. Vincent A, Newland C, Croxen, et al. Genes at the junction -candidates for congenital myasthenic syndromes. Trends Neurosci 1997;20:15-22
47. Abou-Donia MB. Organophosphorus ester-induced delayed neurotoxicity. Annu Rev Pharmacol Toxicol 1981;21:511-548
48. Engel AG, Lambert EH, Gomez MR. A new myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve tetminals and reduced acetylcholine release. Ann Neurol 1977;1:315-330